AVIR Quote, Financials, Valuation and Earnings

Coya Therapeutics, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of -59.36%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Coya Therapeutics, Inc.'s return on equity of -57.41%.

Atea Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 89.27%. On the other hand Coya Therapeutics, Inc. has an analysts' consensus of $16.07 which suggests that it could grow by 166.97%. Given that Coya Therapeutics, Inc. has higher upside potential than Atea Pharmaceuticals, Inc., analysts believe Coya Therapeutics, Inc. is more attractive than Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc. has a beta of 0.159, which suggesting that the stock is 84.143% less volatile than S&P 500. In comparison Coya Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coya Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Coya Therapeutics, Inc. pays out -- of its earnings as a dividend.

Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Coya Therapeutics, Inc. quarterly revenues of $3.6M. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Coya Therapeutics, Inc.'s net income of -$2.1M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Coya Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 25.24x for Coya Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Erasca, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of --. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Erasca, Inc.'s return on equity of -32.03%.

Atea Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 89.27%. On the other hand Erasca, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 52.91%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than Erasca, Inc., analysts believe Atea Pharmaceuticals, Inc. is more attractive than Erasca, Inc..

Atea Pharmaceuticals, Inc. has a beta of 0.159, which suggesting that the stock is 84.143% less volatile than S&P 500. In comparison Erasca, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Erasca, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Erasca, Inc. pays out -- of its earnings as a dividend.

Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Erasca, Inc. quarterly revenues of --. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Erasca, Inc.'s net income of -$30.6M. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Erasca, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus -- for Erasca, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems, Inc. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of -7.48%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat KORU Medical Systems, Inc.'s return on equity of -22.13%.

Atea Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 89.27%. On the other hand KORU Medical Systems, Inc. has an analysts' consensus of $5.56 which suggests that it could fall by -0.14%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than KORU Medical Systems, Inc., analysts believe Atea Pharmaceuticals, Inc. is more attractive than KORU Medical Systems, Inc..

Atea Pharmaceuticals, Inc. has a beta of 0.159, which suggesting that the stock is 84.143% less volatile than S&P 500. In comparison KORU Medical Systems, Inc. has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.435%.

Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. KORU Medical Systems, Inc. pays out -- of its earnings as a dividend.

Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than KORU Medical Systems, Inc. quarterly revenues of $10.4M. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than KORU Medical Systems, Inc.'s net income of -$778K. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while KORU Medical Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 6.57x for KORU Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Atea Pharmaceuticals, Inc.'s net margin of 31.72%. Atea Pharmaceuticals, Inc.'s return on equity of -36.97% beat Eli Lilly & Co.'s return on equity of 106.26%.

Atea Pharmaceuticals, Inc. has a consensus price target of $6.00, signalling upside risk potential of 89.27%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Atea Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Atea Pharmaceuticals, Inc. has a beta of 0.159, which suggesting that the stock is 84.143% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Atea Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Atea Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Atea Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Atea Pharmaceuticals, Inc.'s net income of -$42M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Atea Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atea Pharmaceuticals, Inc. is 0.84x versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.